Oncology Congress

CME/CE INFORMATION

Oncology Congress

Saturday, June 14, 2025 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT

HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it.
Step 2: Complete Evaluations
Click the Evaluations link located in the gray navigation bar (under the event title). You will see a listing of the sessions. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
Step 3: View and Print Certificates
After you’ve completed the evaluations, click the blue Print Certificate button to view and print your CME/CE certificates.

For Pharmacists: Upon completion of the online evaluation(s), your credits will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluations and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Clinical Updates in Myelofibrosis: Improving Equitable Care of Patients
in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Astellas and Pfizer, Inc.; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Regeneron Pharmaceuticals, Inc. This session is supported by an independent medical education grant from GSK.

CREDIT AVAILABLE

Physicians — maximum of 0.5 AMA PRA Category 1 Credit™
Nurses — 0.5 Contact Hour (0.25 contact hour of pharmacotherapy credit)
Pharmacists — 0.5 Contact Hour (0.05 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:

Implement the most recent guideline recommendations for the diagnosis and risk stratification of myelofibrosis
Evaluate the latest clinical trial data on the efficacy and safety of JAK inhibitors and other novel agents for the treatment of myelofibrosis
Develop individualized treatment and adverse effects management plans for patients with myelofibrosis based on the latest evidence and patient-specific factors
Implement strategies to address disparities in myelofibrosis care and treatment in rural and underserved communities

FACULTY
Rami S. Komrokji, MD
Vice Chair, Department of Malignant Hematology
Section Head, Leukemia and MDS
Moffitt Cancer Center
Professor, Department of Oncologic Sciences
University of South Florida
Tampa, FL

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
Past President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-25-049-L01-P)
Type of Activity: Knowledge

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Rami S. Komrokji, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Bristol Myers Squibb, Daiichi Sankyo, Inc., Geron, Jazz Pharmaceuticals, PharmaEssentia, Rigel Pharmaceuticals, Inc., Servier, Sobi, and Sumitomo Pharma Co., Ltd.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Evolving Treatment Approaches for Relapsed/Refractory Multiple Myeloma:
Integrating the Latest Evidence Into the Care of Patients in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

Explain the rationale for use and mechanisms of action of novel next generation of immunomodulatory agents in relapsed/refractory multiple myeloma
Evaluate the latest clinical trial data on the efficacy and safety of immunomodulatory agents in relapsed/refractory multiple myeloma
Apply current evidence and guideline recommendations for treatment of relapsed/refractory multiple myeloma
Implement strategies to address disparities in multiple myeloma care in rural and underserved areas

FACULTY
Joshua R. Richter, MD, FACP
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Multiple Myeloma
Blavatnik Family Chelsea Medical Center
Mount Sinai Hospital
New York, NY

JOINT ACCREDITATION STATEMENT

custom image

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-25-047-L01-P)
Type of Activity: Application

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Joshua R. Richter, MD, FACP, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Bristol Myers Squibb, FORUS Therapeutics, Inc., Genentech, Inc., Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Menarini Group, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceutical Company, Ltd.; speakers’ bureau/honoraria from Adaptive Biotechnologies, Bristol Myers Squibb, Janssen Pharmaceuticals, Inc., and Sanofi.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Addressing Adverse Events Associated With Bispecific Antibody Therapies:
Managing Care for Patients in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:

Identify common adverse events associated with bispecific antibody (BsAb) therapy and the mechanisms contributing to clinical toxicity
Summarize emerging data on bispecific antibodies and associated adverse events
Apply evidence-based strategies and best practices to identify, monitor, and mitigate adverse events associated with BsAb therapy
Employ multidisciplinary strategies for comprehensive, supportive care that meet the complex needs of patients who reside in rural and underserved areas being treated with BsAb therapy

JOINT ACCREDITATION STATEMENT

custom image

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Joshua R. Richter, MD, FACP, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Bristol Myers Squibb, FORUS Therapeutics, Inc., Genentech, Inc., Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Menarini Group, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceutical Company, Ltd.; speakers’ bureau/honoraria from Adaptive Biotechnologies, Bristol Myers Squibb, Janssen Pharmaceuticals, Inc., and Sanofi.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

From Conference to Community: ASCO 2025 Updates to Improve
Breast Cancer Outcomes in Rural and Underserved Settings

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

Summarize recent clinical trial data on novel therapies and evolving treatment strategies for patients with breast cancer
Assess the potential impact of new evidence on the treatment of patients with advanced breast cancer
Incorporate recent data and expert guidance to inform evidence-based, individualized care for patients with breast cancer

FACULTY
Ian E. Krop, MD, PhD
Associate Cancer Center Director, Clinical Research
Professor of Medicine
Yale Cancer Center
Chief Scientific Officer, Translational Breast Cancer Research Consortium
New Haven, CT

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Ian E. Krop, MD, PhD, has disclosed the following relevant financial relationships: advisory board member for ALX Oncology, AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo, Inc., EMD Serono, Inc., Genentech, Inc./Roche, MacroGenics, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., and Seagen, Inc.; grant/research support (awarded to institution) from Genentech, Inc., MacroGenics, Inc., and Pfizer, Inc.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Advancing Equitable Prostate Cancer Care: Evidence-Based Strategies
for Improving Outcomes in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:

Describe risk stratification strategies in prostate cancer and the role of testing, including biomarker testing, imaging, genomic testing, and genetic testing
Assess evolving treatment approaches for nonmetastatic hormone-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, nonmetastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer
Apply clinical evidence to personalized treatment approaches in patients with prostate cancer
Implement strategies to improve coordination of care and increase use of shared decision-making to overcome barriers to prostate cancer care in rural and underserved settings

FACULTY
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, MA

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Alicia K. Morgans, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for Astellas, AstraZeneca Pharmaceuticals, Bayer, Curium, Exelixis, Inc., Janssen Pharmaceuticals, Lantheus, MacroGenics, Inc., Merck & Co., Inc., Myovant Sciences, Myriad Genetics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Sanofi, Sumitomo Pharma America, Inc., and Telix Pharmaceuticals; contracted research for Astellas, Bayer, Janssen Pharmaceuticals, and Pfizer, Inc.; Data and Safety Monitoring Board member for Bristol Myers Squibb.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

CONTACT US

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

System checker: Must meet all requirements of BroadcastMed Live Events Platform
Operating system: Windows or Macintosh
Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
Hardware: computer, smartphone, or tablet
Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.